James A Fagin

James A Fagin

UNVERIFIED PROFILE

Are you James A Fagin?   Register this Author

Register author
James A Fagin

James A Fagin

Publications by authors named "James A Fagin"

Are you James A Fagin?   Register this Author

100Publications

2828Reads

46Profile Views

Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

J Clin Endocrinol Metab 2018 11;103(11):4216-4223

Division of Endocrinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-00803DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194804PMC
November 2018

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Cancer Res 2018 08 14;78(16):4642-4657. Epub 2018 May 14.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-1925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095730PMC
August 2018

Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.

Mol Cell Endocrinol 2018 01 23;460:24-35. Epub 2017 Jun 23.

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita' Federico II c/o Istituto di Endocrinologia e Oncologia Sperimentale, CNR, Via S Pansini 5, 80131 Naples, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2017.06.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741508PMC
January 2018

Biologic and Clinical Perspectives on Thyroid Cancer.

N Engl J Med 2016 12;375(23):2307

National Cancer Institute, Bethesda, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1613118DOI Listing
December 2016

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Cancer Cell 2016 09 11;30(3):485-498. Epub 2016 Aug 11.

Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021590PMC
September 2016

Biologic and Clinical Perspectives on Thyroid Cancer.

N Engl J Med 2016 Sep;375(11):1054-67

From the Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York (J.A.F.); and the Genetics Branch, National Cancer Institute, Bethesda, MD (S.A.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1501993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512163PMC
September 2016

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Cancer Discov 2015 Nov 10;5(11):1178-93. Epub 2015 Sep 10.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642441PMC
November 2015

Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.

Nat Rev Endocrinol 2015 Jun 31;11(6):325-7. Epub 2015 Mar 31.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrendo.2015.53DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518863PMC
June 2015

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

J Clin Oncol 2015 Jan 20;33(1):42-50. Epub 2014 Oct 20.

Mingzhao Xing and Ali S. Alzahrani, Johns Hopkins University School of Medicine; Kathryn A. Carson, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; Young Kee Shong and Tae Yong Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; David Viola and Rossella Elisei, WHO Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, Pisa; Caterina Mian, University of Padua; Federica Vianello, Veneto Institute of Oncology, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua; Efisio Puxeddu, University of Perugia, Perugia; Laura Fugazzola, University of Milan and Fondazione IRCCS CàGranda, Milan; Giovanni Tallini, University of Bologna School of Medicine, Bellaria Hospital, Bologna, Italy; Bela Bendlová and Vlasta Sýkorová, Institute of Endocrinology, Prague, Czech Republic; Linwah Yip, University of Pittsburgh School of Medicine, Pittsburgh, PA; R. Michael Tuttle, Eyal Robenshtok, and James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Agnieszka Czarniecka and Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Christine J. O'Neill, Mark S. Sywak, and Roderick Clifton-Bligh, University of Sydney, Sydney, New South Wales; Alfred K. Lam, Griffith University School of Medicine, Gold Coast, Queensland, Australia; Garcilaso Riesco-Eizaguirre, Hospital La Paz, Health Research Institute, and Hospital Universitario de Móstoles; Garcilaso Riesco-Eizaguirre and Pilar Santisteban, Biomedical Research Institute Alberto Sols, Spanish Council of Research, and Autonomous University of Madrid, Madrid, Spain; Hirotaka Nakayama, Kanagawa Cancer Center, Yokohama, Japan; and Elizabeth H. Holt, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/10/14/JCO.2014.56
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.8253
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.8253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268252PMC
January 2015

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

J Clin Endocrinol Metab 2014 Oct 16;99(10):E1976-87. Epub 2014 Jul 16.

Human Oncology and Pathogenesis Program (R.M., K.-Y.C., T.-Y.K., J.M.D., F.V., S.K.V., J.A.K., J.A.F.) and Department of Medicine (J.A.K., J.A.F.), Memorial Sloan-Kettering Cancer Center, New York, New York 10065; and Division of Endocrinology (B.O.), University of Cincinnati College of Medicine, Cincinnati, Ohio 45267.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2013-3976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184069PMC
October 2014

External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.

J Surg Oncol 2014 Sep 24;110(4):375-82. Epub 2014 Jun 24.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.23656DOI Listing
September 2014

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Endocr Relat Cancer 2014 Apr 7;21(2):371-81. Epub 2014 Mar 7.

Human Oncology and Pathogenesis Program, Department of Medicine Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York, USA Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-13-0499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573438PMC
April 2014

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Endocr Relat Cancer 2013 Oct 21;20(5):659-67. Epub 2013 Aug 21.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-13-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375728PMC
October 2013

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

J Clin Endocrinol Metab 2013 Sep 5;98(9):E1562-6. Epub 2013 Jul 5.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-2383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763971PMC
September 2013

Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.

J Clin Endocrinol Metab 2013 Aug 17;98(8):E1414-21. Epub 2013 Jun 17.

Departments of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-1408DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287446PMC
August 2013

Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

J Clin Endocrinol Metab 2013 May 29;98(5):E962-72. Epub 2013 Mar 29.

Memorial Sloan Kettering Cancer Center-Human Oncology and Pathogenesis Program, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2012-3539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393465PMC
May 2013

STAT3 negatively regulates thyroid tumorigenesis.

Proc Natl Acad Sci U S A 2012 Aug 13;109(35):E2361-70. Epub 2012 Aug 13.

Department of Cancer Biology, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-465 Porto, Portugal.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1201232109
Publisher Site
http://dx.doi.org/10.1073/pnas.1201232109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435219PMC
August 2012

Genome-wide analysis of Pax8 binding provides new insights into thyroid functions.

BMC Genomics 2012 Apr 24;13:147. Epub 2012 Apr 24.

Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-CSIC y Universidad Autónoma de Madrid-UAM, C/Arturo Duperier 4, Madrid 28029, Spain.

View Article

Download full-text PDF

Source
http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2
Publisher Site
http://dx.doi.org/10.1186/1471-2164-13-147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403905PMC
April 2012

Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression.

Thyroid 2011 Aug;21(8):845-53

Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2011.0011DOI Listing
August 2011

Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.

J Clin Endocrinol Metab 2009 Jun 24;94(6):2092-8. Epub 2009 Mar 24.

Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2009-0247DOI Listing
June 2009

Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?

Oncology (Williston Park) 2009 Jun;23(7):592, 600, 603

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
June 2009

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.

Curr Opin Cell Biol 2009 Apr 21;21(2):296-303. Epub 2009 Feb 21.

Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ceb.2009.01.013DOI Listing
April 2009

Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.

Endocr Relat Cancer 2008 Dec 21;15(4):1069-74. Epub 2008 Aug 21.

Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 296, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://erc.endocrinology-journals.org/cgi/doi/10.1677/ERC-08
Publisher Site
http://dx.doi.org/10.1677/ERC-08-0036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648614PMC
December 2008

Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Best Pract Res Clin Endocrinol Metab 2008 Dec;22(6):955-69

Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beem.2008.09.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615540PMC
December 2008

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

J Clin Endocrinol Metab 2008 Nov 19;93(11):4331-41. Epub 2008 Aug 19.

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2008-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582569PMC
November 2008

Refractory thyroid cancer: a paradigm shift in treatment is not far off.

J Clin Oncol 2008 Oct 9;26(29):4701-4. Epub 2008 Jun 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.17.3682DOI Listing
October 2008

The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations.

Authors:
James A Fagin

Trans Am Clin Climatol Assoc 2007 ;118:253-61

Memorial Sloan-Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1863588PMC
July 2008

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

J Clin Endocrinol Metab 2008 Jun 1;93(6):2194-201. Epub 2008 Apr 1.

Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2007-2825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435640PMC
June 2008

[Thyroid cancer: past, present and future].

Arq Bras Endocrinol Metabol 2007 Jul;51(5):641-2

Division of Endocrinology, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0004-27302007000500001DOI Listing
July 2007

Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma.

Thyroid 2007 Feb;17(2):179-80

Division of Endocrinology, Memorial Sloan-Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2006.0093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597468PMC
February 2007

Genetics of papillary thyroid cancer initiation: implications for therapy.

Authors:
James A Fagin

Trans Am Clin Climatol Assoc 2005 ;116:259-69; discussion 269-71

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473144PMC
May 2006

Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications.

Nat Clin Pract Endocrinol Metab 2006 Apr;2(4):180-1

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0547, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncpendmet0161
Publisher Site
http://dx.doi.org/10.1038/ncpendmet0161DOI Listing
April 2006

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Clin Cancer Res 2006 Mar;12(6):1785-93

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0547, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1729DOI Listing
March 2006

BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Endocrinology 2006 Feb 27;147(2):1014-9. Epub 2005 Oct 27.

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Ohio 45267-0547, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2005-0280DOI Listing
February 2006

Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints.

J Biol Chem 2006 Feb 29;281(7):3800-9. Epub 2005 Nov 29.

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, OH 45267, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M511690200DOI Listing
February 2006

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

Cancer Res 2005 May;65(10):4238-45

Division of Endocrinology and Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0547, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-05-0047DOI Listing
May 2005

BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer.

Cell Cycle 2005 Apr 24;4(4):547-8. Epub 2005 Apr 24.

Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0529, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.4.4.1631DOI Listing
April 2005

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

Cancer Res 2005 Mar;65(6):2465-73

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0547, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-04-3314DOI Listing
March 2005

Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens.

Mutat Res 2005 Feb;570(1):17-32

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, PO Box 670547, Cincinnati, OH 45267-0547, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mrfmmm.2004.09.010DOI Listing
February 2005

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

J Clin Invest 2005 Jan;115(1):94-101

Department of Pathology and Laboratory Medicine and Division of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0529, USA.

View Article

Download full-text PDF

Source
http://www.jci.org/articles/view/23237
Publisher Site
http://dx.doi.org/10.1172/JCI23237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC539203PMC
January 2005

Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.

J Clin Endocrinol Metab 2004 Oct;89(10):5175-80

Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche and Dipartimento di Biologia e Patologia Cellulare e Molecolare, University Federico II, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2003-032221DOI Listing
October 2004

Smooth muscle overexpression of IGF-I induces a novel adaptive response to small bowel resection.

Am J Physiol Gastrointest Liver Physiol 2004 Sep 13;287(3):G562-70. Epub 2004 May 13.

Division of Pediatric Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Mediicne, Cincinnati, Ohio 45229-3039, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpgi.00438.2003DOI Listing
September 2004

Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation.

Authors:
James A Fagin

J Clin Endocrinol Metab 2004 Sep;89(9):4264-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2004-1426DOI Listing
September 2004

Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.

J Biol Chem 2003 Dec 10;278(52):52131-8. Epub 2003 Oct 10.

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M306003200
Publisher Site
http://dx.doi.org/10.1074/jbc.M306003200DOI Listing
December 2003

Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.

Oncogene 2003 Oct;22(44):6830-8

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Mail Location 0547, Cincinnati, OH 45267, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1206829
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1206829DOI Listing
October 2003

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

Oncogene 2003 Jul;22(28):4406-12

Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1206602
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1206602DOI Listing
July 2003